With a continuing demand for liver transplantation and a limited organ supply, it is necessary to optimize care at all stages of the transplant continuum. At this timely, informative program, faculty will provide participants with updated information on relevant topics across the transplant process to highlight ways to provide optimal care to transplant patients at all points of their experience.
How can we take steps toward more personalized care of patients living with primary sclerosing cholangitis (PSC)? This intriguing lecture will provide an overview of the latest knowledge on the PSC pathogenesis. Faculty will then expand the discussion to cover potential applications of these advances in the clinic to improve and individualize care of patients with PSC.
This highly anticipated panel discussion provides attendees an exclusive opportunity to hear firsthand from three outstanding leaders in the field. Drs. Harvey J. Alter, Michael Houghton, and Charles M. Rice, the 2020 recipients of the Nobel Prize in Physiology or Medicine, will join TLMdX LIVE for a question and answer session. Their groundbreaking research identified the Hepatitis C virus (HCV) a bloodborne pathogen that causes acute and chronic hepatitis, cirrhosis, and liver cancer and laid the foundation for the future development of a cure.
Yijia Li, James Regan, Jesse Fajnzylber, Kendyll Coxen, Heather Corry, Colline Wong, Alexandra Rosenthal, Caroline Atyeo, Stephanie Fischinger, Elizabeth Gillespie, Rida Chishti, Lindsey Baden, Xu G Yu, Galit Alter, Arthur Kim, Jonathan Z Li – 16 November 2020 – Coronavirus disease 2019 (COVID‐19) is associated with adverse outcomes, including need for invasive mechanical ventilation and death in people with risk factors. Liver enzyme elevation is commonly seen in this group, but its clinical significance remains elusive.
Robert S. Brown – 16 November 2020
Hiroshi Ishiba, Yoshio Sumida, Yuya Seko, Saiyu Tanaka, Masato Yoneda, Hideyuki Hyogo, Masafumi Ono, Hideki Fujii, Yuichiro Eguchi, Yasuaki Suzuki, Masashi Yoneda, Hirokazu Takahashi, Takashi Nakahara, Kojiro Mori, Kazuyuki Kanemasa, Keiji Shimada, Kento Imajo, Kanji Yamaguchi, Takumi Kawaguchi, Atsushi Nakajima, Kazuaki Chayama, Toshihide Shima, Kazuma Fujimoto, Takeshi Okanoue, Yoshito Itoh, the Japan Study Group of NAFLD – 16 November 2020 – This study aimed to examine whether the diagnostic accuracy of four noninvasive tests (NITs) for detecting advanced fibrosis in nonalcoholic fatty l
Join this Practice Guidelines Session to hear experts highlight new recommendations and controversial issues in four new AASLD Guidelines and Guidances developed in 2019-2020. Presenters will be the lead authors of the Guidelines on Autoimmune Hepatitis; Women's Reproductive Health; Ascites and Kidney Injury in Cirrhosis; and Vascular Liver Disorders, Portal Vein Thrombosis and Procedural Bleeding in Patients with Liver Disease.
The global pandemic has affected patients with liver disease in unexpected ways. At this symposium, faculty review the effects of COVID-19 on the liver and how people with liver disease differ in their responses to COVID-19. They will review the latest data on COVID-19 treatments, COVID-19 prevention strategies including vaccines, and racial disparities revealed by this unprecedented epidemic.
As clinicians, how can we improve patient assessment and decision making as we provide individualized care for hepatology patients? Experienced providers will explore persistent issues and potential solutions at this program, with insights ranging from therapeutic adherence to patients' nutritional needs. Ultimately, this engaging sessionâs goal is to provide new information, provoke thoughtful discussion and promote innovation.
Worldwide, alcohol abuse contributes to 50% of cirrhosis cases and 27% of liver-related mortality. Abuse of alcohol and other substances compromises all liver disease outcomes. Can better screening and treatment of substance abuse disorders in patients with liver disease improve clinical outcomes? Find out why multidisciplinary approaches between hepatologists and addiction teams is essential to achieve this goal.